GlaxoSmithKline CEO Andrew Witty attributes the company’s success to sticking to the tried-and-true business model of investing in research and development and not transitioning to an acquisition model.
Witty told CNBC’s “Closing Bell” on Monday that the key is to be patient and to see the value of investing in innovation.
“What we have to stay focused on is the fundamentals of the value of innovation and discovery of medicines and vaccines that make a real difference to patients,” he said.
“We’ve been criticized by people at times for not being exciting enough in terms of embracing the new ideas of how to quickly move things forward. I think the reality of what we’ve seen is there aren’t any shortcuts,” Witty said.
The alternative acquisition model in the health care industry has drawn criticism during this election year. In theory, the M&A strategy can save companies significant sums as they can purchase mature, fully developed products without having to invest in R&D.
“We’ve turned our face away from some of the more novel business model approaches, which often times look interesting in the short run but don’t have legs in the long run,” Whitty said.
Looking forward, GSK wants to continue to innovate and replace their pipeline as older drugs go generic, a process that pressures the revenue streams of pharmaceutical companies.
“Over the last five or six years, we’ve successfully organically replaced about 60 percent of the revenue we had which has gone off patent … That pressure has been on, but we’re coming through that,” Whitty said.
By Christine Wang
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).